Compare Harmony Gold Mining Co. (HMY) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs Novartis AG — how do they compare? Harmony Gold Mining Co. trades at $16.87 (market cap $10.02B), while Novartis AG trades at $143.74 (market cap $268.57B). The key difference: Novartis AG is far larger — about 26.8× Harmony Gold Mining Co.'s market cap, and Harmony Gold Mining Co. pays the higher dividend (4.63%). Which is the better fit depends on your goals — on Pluang, investors hold Harmony Gold Mining Co. for 45 Days and Novartis AG for 82 Days on average.
| HMY | NVS | |
|---|---|---|
Market Cap | $10.02B | $268.57B |
Volume | 3,643,683 | 1,532,573 |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $168.62 |
52-Week Low | $13.32 | $121.80 |
Typical Hold Time | 45 Days | 82 Days |
Enterprise Value | $10.07B | $309.89B |
Dividend Yield | 4.63% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HMY trades at $16.83, up 2.03% today, amid a bearish technical signal from moving averages. The company reported record fiscal 2026 revenue of $99.2B and net income of $29.3B, with a strong net margin of 29.57%. Recent news highlights its strategic shift toward copper production, with the CEO noting the real payoff is expected after 2030. Cash flow from operations surged to $22.65B in 2025, though 2026 projections show a net cash outflow due to heavy investing.
The outlook is mixed: strong fundamentals and undervalued ratios (P/E of 6.02) support upside, but technical weakness and two recent EPS misses pose near-term risks. Analyst consensus is cautious with 70% hold ratings. Key opportunities include copper diversification; risks involve execution on investments and gold price volatility.
Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.
The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
